Tag Archives: Pulmonary Hypertension

FRI in IPF-PH paves the way for Phase IIb trial with INOpulse Device

“The U.S. Food and Drug Administration approved the design of a Phase 2b trial of INOpulse, a device that delivers nitric oxide, as a treatment for patients with pulmonary hypertension associated with lung disease.

INOpulse’s developer, Bellerophon Therapeutics, said the sign-off came after a meeting with the FDA in June. In addition to the Phase 2b design, the meeting covered positive results of the completed Phase 2a iNO-PF trial [using Functional Respiratory Imaging (FRI)] (NCT01457781). That study involved INOpulse’s use in patients with PH associated with idiopathic pulmonary fibrosis.

INOpulse widens narrowed blood vessels, allowing more blood flow to the heart.  The Phase 2a trial achieved its primary objective of widening vessels by increasing blood vessel volume 15.3 percent. The trial also showed a significant association between the blood-vessel widening — or vasodilation — that INOpulse provides and improved ventilation, or movement of air in and out of the lungs.”

Read more

 

 

 

Figure 1. Changes in blood vessel volume after administration of iNO: Green indicates a positive regional increase in blood vessel volume, red indicates a reduction in blood vessel volume

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017